<SEC-DOCUMENT>0000929638-23-003305.txt : 20231129
<SEC-HEADER>0000929638-23-003305.hdr.sgml : 20231129
<ACCEPTANCE-DATETIME>20231129165053
ACCESSION NUMBER:		0000929638-23-003305
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20231127
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231129
DATE AS OF CHANGE:		20231129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			enGene Holdings Inc.
		CENTRAL INDEX KEY:			0001980845
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41854
		FILM NUMBER:		231453010

	BUSINESS ADDRESS:	
		STREET 1:		4868 RUE LEVY, SUITE 220
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4R 2P1
		BUSINESS PHONE:		(514) 332-4888

	MAIL ADDRESS:	
		STREET 1:		4868 RUE LEVY, SUITE 220
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4R 2P1
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:engn="http://engene.com/20231127" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Morgan Lewis
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_19bd0de46b044ca39ca9fe10f63ccb52" contextRef="c20231127to20231127" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_1a57d70afcb3446c996aa23ebf449804" contextRef="c20231127to20231127">0001980845</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_c11de306c13a4ad19ac39a5b89a2585b" contextRef="c20231127to20231127">00-0000000</ix:nonNumeric><ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_f7354d9afe2c4baaa48fe6e994b351b3" contextRef="c20231127to20231127" format="ixt:fixed-true">true</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="engn-20231127.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20231127to20231127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-27</xbrli:startDate><xbrli:endDate>2023-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:CommonsharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-27</xbrli:startDate><xbrli:endDate>2023-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001980845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-27</xbrli:startDate><xbrli:endDate>2023-11-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><br />
  </div>

  <div style="font-family: 'Times New Roman', Times, serif;">
    <div style="color: #000000;">
      <div>
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="padding-bottom: 6pt; text-align: center;"> _______________________<br />
      </div>

      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_3a474c3cd0b14564bc1df8d0899406bb" contextRef="c20231127to20231127">8-K</ix:nonNumeric></div>

      <div style="text-align: center; font-weight: bold; font-size: 12pt;"> <span style="font-weight: normal;">____________________</span> </div>

      <div style="text-align: center; font-weight: bold; font-size: 12pt;"> <br />
      </div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div><span style="font-weight: bold;"> </span></div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>

      <div><span style="font-weight: bold;"> </span></div>

      <div style="font-size: 10pt;"><span style="font-weight: bold;"> </span><br />
      </div>

      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_e15f5e7317774f4799b469f72056e9b7" contextRef="c20231127to20231127" format="ixt:date-monthname-day-year-en">November 27, 2023</ix:nonNumeric></div>

      <div style="font-size: 12pt;"> <br />
      </div>

      <div style="text-align: center; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_94ce083d0b124e88855fd6838329e1ae" contextRef="c20231127to20231127">enGene Holdings Inc.</ix:nonNumeric><br />
      </div>

      <div style="font-size: 10pt; text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter) </div>

      <div style="font-size: 10pt; padding-bottom: 12pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_db44afcc1ab243bf9f4dd2d2e3958ba6" contextRef="c20231127to20231127" format="ixt-sec:edgarprovcountryen">British Columbia, Canada</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 5%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_b8c027e36a1944e3bb37c88c468a5351" contextRef="c20231127to20231127">001-41854</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 5%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; text-align: center; font-weight: bold;"><span style="-sec-ix-hidden:Fact_c11de306c13a4ad19ac39a5b89a2585b">N/A</span></td>

  </tr>

  <tr>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(State or other jurisdiction <br />
                of incorporation)</div>
            </td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(Commission <br />
                File Number)</div>
            </td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(IRS Employer <br />
                Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 8pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid #000000; text-align: center; font-size: 10pt; font-weight: bold;">
              <div><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_03d68e7fef564c30bab6f3c69a3f3cf0" contextRef="c20231127to20231127">4868 Rue Levy, Suite 220</ix:nonNumeric></div>
              <div><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_2c71d323120248c19469aecc08c8970b" contextRef="c20231127to20231127">Saint-Laurent</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_e5023309776344e6abe3bc39072eb58d" contextRef="c20231127to20231127">QC</ix:nonNumeric>,
                Canada<br />
              </div>
            </td>

    <td style="width: 6%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
              <div style="text-align: left;">&#160;</div>
            </td>

    <td style="width: 47%; vertical-align: bottom; text-align: center; font-size: 10pt; border-bottom: 2px solid #000000; font-weight: bold">
              <div><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_0a33e3eb295647b8a7e054ebca406b44" contextRef="c20231127to20231127">H4R 2P1</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 47%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(Address of principal executive offices)</div>
            </td>

    <td style="width: 6%; vertical-align: bottom; font-size: 10pt;">
              <div style="text-align: left; ">&#160;</div>
            </td>

    <td style="width: 47.48%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; ">(Zip code)</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"> <br />
      </div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;">Registrant's telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_86a3f038e44141dea0045d88c459587b" contextRef="c20231127to20231127">514</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_83278cb0fc20428c8db846e1145b0f95" contextRef="c20231127to20231127">332-4888</ix:nonNumeric></div>

      <div style="font-size: 10pt;"> <br />
      </div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;"><br />
      </div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160; </span><span style="text-decoration: underline;"><span style="text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; </span></span><span style="text-decoration: underline;"><span style="text-decoration: underline;"><span style="text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; </span></span>Not applicable</span><span style="text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; </span><span style="text-decoration: underline;"><span style="text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; </span>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160;
          &#160; &#160; &#160; &#160;&#160;&#160;&#160; </span> </div>

      <div><span style="font-weight: bold;"> </span></div>

      <div style="text-align: center; font-size: 10pt; font-weight: bold;">(Former Name or Former Address, if Changed Since Last Report)</div>

      <div><span style="font-weight: bold;"> </span></div>

      <div style="font-size: 10pt;"><span style="font-weight: bold;"> </span><br />
      </div>

      <div style="font-size: 10pt;">
<div><span style="font-weight: bold;"> </span></div>

        <div style="text-align: left; margin-top: 6pt; margin-bottom: 6pt; font-size: 10pt;"> Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
          provisions (see General Instruction A.2. below): </div>

        <div style="text-align: left; margin-bottom: 7.1pt; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_16a8d6eb3e8d4273b030f8b28f7584d9" contextRef="c20231127to20231127" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities
          Act (17 CFR 230.425)</div>

        <div style="text-align: left; margin-bottom: 6.95pt; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_ec49170c63bd4d78bac6ef8314bb1677" contextRef="c20231127to20231127" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange
          Act (17 CFR 240.14a-12)</div>

        <div style="text-align: left; margin-bottom: 6.95pt; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_d9b7b0596b1943499f163fa58f87b76c" contextRef="c20231127to20231127" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under
          the Exchange Act (17 CFR 240.14d-2(b))</div>

        <div style="text-align: left; margin-bottom: 2.05pt; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_327111642f23450c8c0b3e8a8e9885ec" contextRef="c20231127to20231127" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under
          the Exchange Act (17 CFR 240.13e-4(c))</div>

        <div style="margin-bottom: 2.05pt; font-size: 10pt;">&#160;</div>

      </div>

      <div style="font-size: 10pt;"><span style="font-weight: bold;"> </span><br />
      </div>

      <div style="text-align: center; font-size: 10pt;"><span style="text-decoration: underline;">Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</span></div>

      <div style="text-align: center; font-size: 10pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">Title of each class</span></div>
            </td>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">Trading Symbol(s)</span></div>
            </td>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">Name of each exchange on which registered</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_7d3dbc899a4d4cab87e769e74c0d9db9" contextRef="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember">Common shares</ix:nonNumeric></td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_91b848d0c3ee4d5eb1c9e6d183f87888" contextRef="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember">ENGN</ix:nonNumeric></td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_c73b4e041cf941eaa9198d40cc41b25b" contextRef="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c276d320959b4de1b532dbd9de158016" contextRef="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember">Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share</ix:nonNumeric><br />
            </td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_fb4a7e565bd14ea8bf43bbe744805ea3" contextRef="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember">ENGNW</ix:nonNumeric></td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_946969cf15334e75929a8cf43c102bfa" contextRef="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
            </td>

  </tr>


</table>
      <div style="margin-top: 6pt; margin-bottom: 6pt; font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
        of 1934 (&#167;240.12b-2 of this chapter):</div>

      <div><br />
      </div>

      <div style="text-align: left; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_82788dc468f34561b49979e06ee86098" contextRef="c20231127to20231127" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div><br />
      </div>

      <div style="text-align: left; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
        provided pursuant to Section 13(a) of the Exchange Act. &#9746;</div>

      <div style="margin-top: 6pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

    </div>

  </div>

  <div>
    <div> <br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Item 5.02.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="text-decoration: underline;">Appointment of Chief Financial Officer</span></div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On November 27, 2023, Ryan Daws became Chief Financial Officer (&#8220;CFO&#8221;) and Head of Business Development of enGene Holdings
      Inc. (&#8220;enGene&#8221; or the &#8220;Company&#8221;).</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mr. Daws, 49, joined the Company from Obsidian Therapeutics, Inc., where he was Chief Financial Officer and Head of
      Business Development from July 2019 to November 2023. Prior to that, from June 2017 to March 2019, he served as a Managing Director in the Healthcare Investment Banking Group at Robert W. Baird &amp; Co. with a focus on life sciences companies. Prior
      to Baird, Mr. Daws was the Chief Financial Officer and Head of Business Development of Concert Pharmaceuticals, Inc. from January 2014 to June 2017, and a life-science-focused investment banker at Stifel, Nicolaus and Company from September 2010 to
      June 2013.</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mr. Daws replaced Alexandre Grassin as the Company&#8217;s principal financial officer and principal accounting officer.</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mr. Daws will be entitled to an annual base salary of $440,000, to an annual 40% bonus opportunity, and to participate in
      employee benefit plans.&#160; Mr. Daws is also entitled to a cash signing bonus in the amount of $143,500, which is payable in the first payroll period of 2024, and which shall be deemed earned upon completion of one full year of active employment with
      the Company. Additionally, upon enGene&#8217;s filing of a Form S-8 with the U.S. Securities and Exchange Commission to register the common shares of the Company (&#8220;Common Shares&#8221;) underlying stock options awarded pursuant to the Company&#8217;s Incentive Equity
      Plan, Mr. Daws shall become eligible to receive a grant of an option to acquire 232,000 Common Shares at an exercise price equal to the fair value of such Common Shares on the date of the grant, vesting in equal tranches over four years, with the
      first such tranche to vest on November 27, 2024, and each subsequent tranche to vest on the subsequent one-year anniversary thereof.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, Mr. Daws has agreed to standard restrictive covenant obligations, including a noncompete and nonsolicit
      obligation which runs while employed and for twelve months thereafter.</div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pending finalization of an employment agreement with the Company&#8217;s subsidiary, enGene USA, Inc., the terms of Mr. Daws&#8217;s
      employment will be governed by the Offer Letter dated November 13, 2023, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.</div>

    <div><br />
    </div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="text-decoration: underline;">&#160;Employment Agreement with Chief Medical Officer</span></div>

    <div><br />
    </div>

    <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On November 29, 2023, Dr. Richard Bryce, the Company&#8217;s Chief Medical Officer, and enGene USA, Inc. entered into an
      Executive Employment Agreement, effective as of November 15, 2023, (the &#8220;Bryce Employment Agreement&#8221;)</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Bryce Employment Agreement has no fixed term and is terminable at will. Dr. Bryce is entitled under the Bryce
      Employment Agreement to an annual base salary of $450,000, to an annual 40% bonus opportunity (which shall be prorated based on Dr. Bryce&#8217;s employment during 2023), and to participate in enGene USA&#8217;s employee benefit plans.&#160; For 2024, Dr. Bryce shall
      be eligible for a nonqualified stock option grant to acquire 153,000 common shares of enGene, subject to the terms and conditions of the enGene 2023 Incentive Equity Plan.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Bryce Employment Agreement, (a) upon the termination of Dr. Bryce&#8217;s employment by enGene USA without
      Cause (as defined in the Bryce Employment Agreement) or by Dr. Bryce for Good Reason (as defined in the Bryce Employment Agreement), Dr. Bryce is entitled to receive post-termination severance benefits from enGene USA consisting of (i) twelve months&#8217;
      base salary, (ii) twelve months of continued health insurance benefits, (iii) a prorated portion of his annual bonus, if such termination occurs six months or more into the applicable performance period for such annual bonus, and (iv) acceleration
      and vesting of any then unvested time-based equity awards that would have vested in the twelve-month period following such termination; and (b) upon the termination of Dr. Bryce by enGene USA without Cause or by Dr. Bryce for Good Reason during a
      change in control period, which includes the ninety days prior to and twelve months following a change in control, Dr. Bryce is entitled to</div>

    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">receive post-termination severance benefits from enGene USA consisting of (i) twelve months&#8217; base salary, (ii) an amount equal to his
      annual bonus opportunity at the target level, (iii) twelve months of post-termination health insurance benefits; and (iv) acceleration and vesting of all then unvested time-based equity awards.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, pursuant to the Bryce Employment Agreement, Dr. Bryce has agreed to standard restrictive covenant
      obligations, including a noncompete and nonsolicit obligation which runs while employed and for twelve months thereafter.</div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This summary is qualified in its entirety by reference to the text of the Bryce Employment Agreement, a copy of which is
      filed as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Item 7.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Regulation FD Disclosure.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div>
      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On November 29, 2023, the Company issued a news release with respect to the appointment of Mr. Daws as Chief Financial
        Officer and Head of Business Development of the Company, a copy of which is furnished with this Form&#160;8-K as Exhibit&#160;99.1 and incorporated into this Item 7.01 by reference. The information in this Item 7.01 of Form&#160;8-K shall not be deemed to be
        &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of such section, nor shall such information be deemed incorporated by reference in any filing
        under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.</div>

    </div>

    <div><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"> </span><br />
    </div>

    <div><br />
    </div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12%; vertical-align: top; border-bottom: 2px double black;">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td style="width: 86%; vertical-align: top; border-bottom: 2px double black;">
            <div>
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Exhibit</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit10-1.htm">10.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 86%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit10-1.htm">Employment Offer Letter, dated November 13,
                2023, by and between enGene USA, Inc. and Ryan Daws.*</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit10-2.htm">10.2</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 86%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit10-2.htm">Employment Agreement, dated November 29,
                2023, by and between enGene USA, Inc. and Richard Bryce.*</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit99-1.htm">99.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 86%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit99-1.htm">Press Release of the Company, dated as of
                November 29, 2023.*</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="engn-20231127.xsd">104</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 86%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="engn-20231127.xsd">Cover Page Interactive Data File
                (formatted as Inline XBRL).</a></div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">*</span><span class="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.14pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Indicates a management contract or compensatory plan or arrangement.</span></div>

    <div style="text-align: center;"><br />
    </div>

    <div>&#160;</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

    <div>&#160;</div>

    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.98%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ENGENE HOLDINGS INC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.98%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.98%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 29, 2023</div>
          </td>

    <td style="width: 2%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:&#160; <br />
            </div>
          </td>

    <td style="border-bottom: 1px solid #000000; vertical-align: top; width: 48%;">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Jason D. Hanson</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.98%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 48%; vertical-align: top;">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Jason D. Hanson</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.98%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 48%; vertical-align: top;">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title: Chief Executive Officer</div>
            </div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div><br />
    </div>

    <div><br />
    </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit10-1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Morgan Lewis
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">EXHIBIT 10.1</div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z16cc50ba7f8a437184fb9d8a9d2a67ab" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><img src="engene_logo.jpg"></td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">177 Huntington Avenue</font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif';"><br>
              </font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Suite 1703 PMB 97584</font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif';"><br>
              </font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Boston, MA 02115</font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif';">-&#160;</font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">3153</font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif';"><br>
              </font><font style="font-size: 6pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">www.engene.com</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="color: rgb(3, 3, 3); font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">November 10, 2023</div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zea082c4d1a0a4da0b074e8533df54a71" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">TO:</td>
          <td style="width: auto; vertical-align: top;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Ryan Daws</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';"><br>
              </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">[ADDRESS REDACTED]</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';"><br>
                <br>
              </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Offer of Employment for the position of Chief Financial Officer</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="color: rgb(3, 3, 3); font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">RE:</div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="color: rgb(3, 3, 3); font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">Dear Ryan,</div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="text-align: justify; color: rgb(3, 3, 3); font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">It is a pleasure to offer you the position of Chief Financial Officer at enGene USA Inc. (the "Company" or "enGene"), reporting to Jason
      Hanson, Chief Executive Officer ("CEO"). Our offer includes the following:</div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zde4a206a094046ae9a95d582f4e5c3dc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">A Base Salary of four hundred forty thousand dollars ($440,000 USO) per annum paid semi</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">- </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">monthly in 24 equal installments.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zd895799b839b49f3a8cf1b7cacfc2417" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: rgb(3, 3, 3); font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Bonus: You will be eligible to receive a bonus upon achievement of goals to be set at the beginning of each year. You will be entitled to
                receive, at target, a Bonus of up to 40% of Base Salary. The terms of the bonus plan may change each year at the Company's discretion</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">.&#160;</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">The Bonus for 2023 will be</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z42be70027b9e4b91a0229c3745bcd4b1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">$143,500, payable in the first payroll period of 2024. The Bonus will not actually be deemed earned until you have completed one full year of
                active employment with the Company in good standing</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zfbd5e81086854150a673cc1bd2842dae" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: rgb(3, 3, 3); font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Stock Options: Subject to and upon consummation of the business combination transactions contemplated under the BCA (as defined below), you will
                be eligible for incentive equity grants from time to time during your period of employment as approved by the board of directors of Parent (as defined below) or its compensation committee, as applicable. At the first meeting of the
                compensation committee of the board of directors of Parent that occurs after the consummation of the business combination transactions contemplated under the BCA and a registration statement on Form S</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">-</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">8 is filed with the U</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(29, 29, 29);">.</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">S</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(75, 75, 75);">.&#160;</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Securities and Exchange Commission in respect of the common shares of parent underlying your stock options, the
                Company will request that Parent present to its compensation committee, and that Parent recommend that its compensation committee approve, a proposal for the grant to you of an option to acquire 232,000 Class A common shares of Parent at an
                exercise price equal to the fair market value of such common shares on the date of grant, vesting in equal tranches over four years, with the first such tranche to vest on the date that is one year from the date of hire and each subsequent
                tranche to vest on the subsequent one</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">-</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">year anniversary
                thereof. For purposes of this offer letter, (i) the term "Parent" means enGene Holdings Inc., a Canadian corporation that will become the ultimate parent company of the Company subject to, and upon, the consummation of the business
                combination transactions contemplated under the BCA, and (ii) the term </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(29, 29, 29);">"BCA" </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">means that certain Business Combination Agreement, dated as of May 16, 2023, by and among enGene Inc., a Canadian corporation that is the direct parent company of the Company, and Forbion
                European Acquisition Corp., among others.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="zedda8bdc78dc499fbd5d11d798f8327c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; color: rgb(3, 3, 3); font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Paid Holidays: Presently enGene USA does not have a formal sick, vacation or paid time off policy. You may request PTO as you see fit</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(79, 79, 79);">. </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Vacations may not exceed two weeks at any
                given time without the consent of the CEO. These days are neither accruable nor payable upon cessation of employment</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(79, 79, 79);">.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z241ad9d22c364c4b835cc9816bc283c4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">You will be eligible to participate in the standard benefit programs made available generally to the Company employees, including 401K Plan, medical insurance, dental insurance, and life insurance, subject to
              the terms and conditions of applicable plans and policies. Benefit programs are subject to change or termination at any time at the Company's discretion.</div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z54e7338089d041adaa50decdc6235406" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">All payments and benefits described in this offer letter or that you may otherwise be entitled or eligible to receive as a result of our
                employment with the Company will be subject to applicable federal, state and local tax withholdings</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(79, 79, 79);">.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z773ad3de119f4c8baa1669266a509ce5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">As a condition of your employment. You must sign and abide by the Company's standard Employee Proprietary Information, Inventions, Non</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">-</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Competition and Non</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">-</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Solicitation Agreement (the </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(28, 28, 28);">"Proprietary </font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Information Agreement"), a copy of which is enclosed. In addition, final appointment is contingent
                upon the satisfactory completion of reference checks and a background investigation. As a Company employee, you will be expected to abide by any and all policies and procedures that are generally applicable to employees of the Company, as
                such policies and procedures may be in effect from time to time.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z5b91072f47bc407491c85bbcae9d7877" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">It is understood that you are an "at</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">-</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">will" employee</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(56, 56, 56);">.&#160;</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason
                without prior notice and without additional compensation to you.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z3538ee1b23164c699232c6d20796992a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">In making this offer, the Company understands, and in accepting it you represent that, you are not under any obligation to any former employer or any person, firm, or corporation which would prevent, limit, or
              impair in any way the performance by you of your duties as an employee of the Company (including, <font style="color: rgb(3, 3, 3);">but not limited to, any non</font>-<font style="color: rgb(3, 3, 3);">compete agreements). Moreover, you
                agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting, or other business activity directly related to the business in which the Company is now involved or
                becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly, you agree not to bring any third</font>-&#160;<font style="color: rgb(3, 3, 3);">party
                confidential information to the Company, including that of your former employer, and that you will not in any way utilize any such information in performing your duties for the Company.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z793cccb4a6984765a10079c8e5899d55" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">This Letter, along with the Proprietary Information Agreement, sets forth the complete and exclusive agreement between you and the Company with
                regard to your employment with the Company, and supersedes many prior representations or agreements about this matter, weather written or verbal. This letter may not be modified or amended except by a written agreement signed by you and the
                CEO and President of the Company or an authorized member of the Board. It is anticipated that this agreement will be superseded by an employment agreement as soon as possible, the terms of which have been previously discussed</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4feab7c2872d4c588dff16050f1fc89c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">This letter shall be governed by and construed in accordance with the internal substantive laws of the Commonwealth of Massachusetts. You hereby agree to consent to personal jurisdiction of the state and
              federal courts situated within the Commonwealth of Massachusetts for purposes of enforcing this letter,</div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z833645e3b3e149e79c9f91d5e199d7aa" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">and waive any objection that you might have to personal jurisdiction or venue in those courts. EACH OF THE COMPANY AND YOU HEREBY WAIVES ANY
                RIGHT TO A JURY TRIAL, AND TO CLAIM OR RECOVER PUNITIVE DAMAGES</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(89, 89, 89);">.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z590415f1b4a04a07aad7b51b307b73e3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">Your official start date will be November 27, 2023</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif';">.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zc4caf703562049a2b9be5d5d6abdef9b" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">The selection process has been rigorous, and we are pleased with the prospect of you joining as our newest team member. We await your acceptance
                and look forward to welcoming aboard</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(65, 65, 65);">.</font></div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z9b0d5d3689f34735a061668f859599b0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">Sincerely,</div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="za7265762ded24569b67a4fc39fd31f38" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div>/s/ Jason D. Hanson</div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7e849a75e0f24e18966c649f692b9e4a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">Jason D. Hanson<br>
              Chief Executive Officer &amp; President</div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z8397f5b7921e4f62a64276c8b2368501" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
          </td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(3, 3, 3);">I accept the employment offer stated above</font><font style="font-size: 9pt; font-family: Arial,Helvetica,'sans-serif'; color: rgb(65, 65, 65);">.</font></div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z156545794d0b4c6b9df6935e9e057145" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">&#160;</td>
          <td style="border-bottom: 1px solid #000000; vertical-align: top; width: 45%; font-family: Arial, Helvetica, 'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">/s/ Ryan Daws</div>
          </td>
          <td style="width: auto; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">&#160;</td>
          <td style="border-bottom: 1px solid #000000; vertical-align: top; width: 45%; font-family: Arial, Helvetica, 'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">Nov 13, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 18pt; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">&#160;</td>
          <td style="width: 45%; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">Ryan Daws</div>
          </td>
          <td style="width: auto; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">&#160;</td>
          <td style="width: 45%; vertical-align: top; font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;">
            <div style="color: rgb(3, 3, 3);">Date</div>
          </td>
        </tr>

    </table>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div style="font-family: Arial,Helvetica,'sans-serif'; font-size: 9pt;"><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit10-2.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Morgan Lewis
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right;">EXHIBIT 10.2</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">EMPLOYMENT AGREEMENT FOR DR. RICHARD BRYCE</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">THIS EMPLOYMENT AGREEMENT (this &#8220;<u>Agreement</u>&#8221;) is entered into by and between EnGene USA, Inc., its successors and assigns. (the &#8220;<u>Company</u>&#8221;) and Dr. Richard Bryce (the &#8220;<u>Executive</u>&#8221;)
      as of the date first written below.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">WHEREAS, the Company desires to continue to employ the Executive as its Chief Medical Officer and the Executive desires to serve in such capacity on behalf of the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the Company and the Executive hereby agree as follows:</div>
    <div>&#160;</div>
    <div>1.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Employment</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Term</u>.&#160; The initial term of this Agreement shall begin on November 15, 2023 (the &#8220;<u>Effective
        Date</u>&#8221;) and shall continue until the termination of the Executive&#8217;s employment.&#160; The period commencing on the Effective Date and ending on the date on which the term of this Agreement terminates is referred to herein as the &#8220;<u>Term</u>.&#8221;&#160; The
      Executive&#8217;s employment during the Term shall be as an &#8220;at-will&#8221; employee; the Executive may resign his employment at any time, and the Company may terminate the Executive&#8217;s employment at any time, for any reason or no reason, subject to the
      provisions of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Duties</u>.&#160; During the Term, the Executive shall serve as the Chief Medical Officer, with such
      duties, responsibilities, and authority commensurate therewith, and shall report to the Chief Executive Officer of the Company (the &#8220;<u>CEO</u>&#8221;). The Executive shall perform all duties and accept all responsibilities incident to such position as may
      be reasonably assigned to the Executive by the CEO that are consistent with and within the scope of Executive&#8217;s position.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><u>Best Efforts</u>.&#160; During the Term, the Executive shall devote the Executive&#8217;s best efforts and
      full business time and attention to promote the business and affairs of the Company and its affiliated entities, and shall be engaged in other business activities only to the extent that such activities do not materially interfere or conflict with
      the Executive&#8217;s obligations to the Company hereunder, including, without limitation, obligations pursuant to Section 15 below.&#160; The foregoing shall not be construed as preventing the Executive from (i) serving on civic, educational, philanthropic or
      charitable boards or committees, or, with the prior written consent of the CEO, which shall not be unreasonably withheld,&#160; on corporate, advisory or scientific advisory boards, or service in an advisory capacity to a corporate entity and (ii)
      managing personal investments , so long as such activities are permitted under the Company&#8217;s Code of Conduct and employment policies and do not violate the provisions of Section 15 below.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><u>Principal Place of Employment</u>.&#160; The Executive understands and agrees that the Executive&#8217;s
      principal place of employment will be in the Executive&#8217;s home office in Texas, and that employment will remain remote but the Executive will be required to travel the Company&#8217;s headquarters in or around Boston, Massachusetts (&#8220;<u>Principal Place of
        Employment</u>&#8221;). The Executive&#8217;s employment and all services hereunder shall be provided in the United States and the Executive shall not be required to work in Canada during the Term of this Agreement.&#160; Executive will be required to travel for
      business in the course of performing the Executive&#8217;s duties for the Company.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">2.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Compensation</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Base Salary</u>.&#160; During the Term, the Company shall pay the Executive a base salary (&#8220;<u>Base
        Salary</u>&#8221;), at the annual rate of $450,000, which shall be paid in installments in accordance with the Company&#8217;s normal payroll practices.&#160; The Executive&#8217;s Base Salary shall be reviewed annually by the Compensation Committee (the &#8220;<u>Compensation
        Committee</u>&#8221;) of the Board of Directors (the &#8220;<u>Parent Board</u>&#8221;) of EnGene Holdings Inc. (&#8220;<u>Parent</u>&#8221;), and may be increased, but not decreased.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><u>Annual Bonus</u>.&#160; The Executive shall be eligible to receive an annual bonus for each&#160; calendar
      year during the Term, commencing with the 2024 calendar year, based on the attainment of individual and corporate performance goals and targets established by the Compensation Committee (&#8220;<u>Annual Bonus</u>&#8221;).&#160; The target amount of the Executive&#8217;s
      Annual Bonus for any calendar year during the Term is 40% of the Executive&#8217;s annual Base Salary (the &#8220;<u>Target Annual Bonus</u>&#8221;).&#160; For calendar year 2023, the Executive&#8217;s Annual Bonus will be governed by the terms and applicable targets in place
      immediately prior to the Effective Date and be prorated based on the Executive&#8217;s employment during 2023.&#160; Any Annual Bonus shall be paid after the end of the calendar year to which it relates, at the same time and under the same terms and conditions
      as the bonuses are paid to other executives of the Company; provided, that, in no event shall the Executive&#8217;s Annual Bonus be paid later than two and a half months after the last day of the calendar year to which the Annual Bonus relates.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Equity Compensation</u>.&#160; The Executive shall be eligible to participate in the Engene Holdings
      Inc. 2023 Incentive Equity Plan (the &#8220;<u>Equity Plan</u>&#8221;) at a level commensurate with similarly situated C-Suite executives of the Company, as determined in the sole discretion of the Compensation Committee.&#160; For 2024, the Executive shall be
      eligible for a nonqualified stock option grant to acquire 153,000 common shares of the Parent, on the terms and subject to the conditions set forth in the Equity Plan and as set forth the Executive&#8217;s offer letter with the Company dated August 31,
      2023.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">3.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Retirement and Welfare Benefits</u>.&#160; During the Term, the Executive shall be eligible to participate in the
      Company&#8217;s health, life insurance, long-term disability, retirement and welfare benefit plans and programs, pursuant to their respective terms and conditions.&#160; Nothing in this Agreement shall preclude the Company or any Affiliate of the Company from
      terminating or amending any employee benefit plan or program from time to time after the Effective Date.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">4.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Vacation</u>.&#160; During the Term, the Executive shall be eligible to vacation each year and holiday and sick leave at
      levels commensurate with those provided to similarly situated US executives of the Company, in accordance with the Company&#8217;s policy and/or practice which as of the Effective Date is an unlimited policy.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">5.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Business Expenses</u>.&#160; The Company shall reimburse the Executive for all necessary and reasonable travel (which
      does not include commuting to Executive&#8217;s Principal Place of Employment) and other business expenses incurred by the Executive in the performance of his duties hereunder in accordance with such policies and procedures as the Company may adopt
      generally from time to time for executives.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">6.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Termination of Employment Without Cause; Resignation for Good Reason</u>.&#160; If the Executive&#8217;s employment is
      terminated by the Company without Cause or by the Executive for Good Reason, the provisions of this Section 6 shall apply.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(a)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>The Company may terminate the Executive&#8217;s employment with the Company at any time without Cause upon
      not less than thirty (30) days&#8217; prior written notice to the Executive and the Executive may resign for Good Reason.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(b)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Unless the Executive complies with the provisions of Section 6(c) below, upon termination of
      employment under Section 6(a) above, no other payments or benefits shall be due under this Agreement to the Executive other than the Accrued Obligations.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(c)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Notwithstanding the provisions of Section 6(b) above, upon termination of employment under Section
      6(a) above, if the Executive executes and does not revoke the Release, and so long as the Executive continues to comply with the provisions of Section 15 below, in addition to the Accrued Obligations, the Executive shall be entitled to receive the
      following:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 144pt;">(i)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Continuation of the Executive&#8217;s Base Salary for a twelve (12) month period (the &#8220;<u>Severance Term</u>&#8221;),

      at the rate in effect for the year in which the Executive&#8217;s date of termination of employment occurs, which amount shall be paid in regular payroll installments over the Severance Term; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 144pt;">(ii)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>If the Executive timely and properly elects health continuation coverage under the Consolidated
      Omnibus Budget Reconciliation Act of 1985 (&#8220;<u>COBRA</u>&#8221;), then continued health (including hospitalization, medical, dental, vision etc.) insurance coverage substantially similar in all material respects as the coverage provided to other Company
      employees for the Severance Term; provided that the Executive shall pay the employee portion of such coverage, if any, the period of COBRA health care continuation coverage provided under section 4980B of the Code shall run concurrently with the
      Severance Term, and notwithstanding the foregoing, the amount of any benefits provided by this subsection (ii) shall be reduced or eliminated to the extent the Executive obtains duplicative benefits by virtue of the Executive&#8217;s subsequent or other
      employment. Notwithstanding the foregoing, if the Company&#8217;s making payments under this Section 6(c) would violate any nondiscrimination rules applicable to the Company&#8217;s group health plan under which such coverage is made available, or result in the
      imposition of penalties under the Code or the Affordable Care Act, the Parties agree to reform this Section 6(c) in a manner as is necessary to comply with such requirements and avoid such penalties.</div>
    <div>&#160;</div>
    <div style="text-indent: 108pt;">(iii)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;&#160; </font>An amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive
      was employed prior to such termination, payable within forty-five (45) days of Executive&#8217;s termination of employment; provided, that such termination occurs six months or more into the applicable performance period for such Annual Bonus;</div>
    <div>&#160;</div>
    <div style="text-indent: 108pt;">(iv)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;&#160; </font>Any time-based equity awards shall accelerate and vest with respect to the number of shares underlying the equity
      awards that would vest over the Severance Term had the Executive remained employed for such Severance Term and any equity awards that are subject to performance-based vesting shall vest and become exercisable, if at all, subject to the terms of such
      equity awards.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">7.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Change in Control.</u> Notwithstanding anything to the contrary herein, if there is a CIC Termination, then the
      provisions of this Section 7 shall apply.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Unless the Executive complies with the provisions of Section 7(b) below, upon CIC Termination, no
      other payments or benefits shall be due under this Agreement to the Executive other than the Accrued Obligations.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(b)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Notwithstanding the provisions of Section 7(a) above, upon CIC Termination, if the Executive
      executes and does not revoke the Release, and so long as the Executive continues to comply with the provisions of Section 15 below, then, in addition to the Accrued Obligations, the Executive shall be entitled to receive the following:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 144pt;">(i)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Continuation of the Executive&#8217;s Base Salary for twelve (12) month period (the &#8220;<u>CIC Severance
        Term</u>&#8221;), at the rate in effect for the year in which the Executive&#8217;s date of termination of employment occurs, which amount shall be paid in regular payroll installments over the CIC Severance Term;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 144pt;">(ii)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>An amount equal to the Annual Target Bonus, payable within forty-five (45) days of Executive&#8217;s
      termination of employment;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 144pt;">(iii)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>COBRA continuation benefits as set forth in Section 6(c)(iii), except that the Severance Term
      shall be the CIC Severance Term; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 144pt;">(iv)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>All time-based equity awards shall accelerate and become fully vested and any equity awards that
      are subject to performance-based vesting shall vest, if at all, subject to the terms of such equity awards.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">8.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Cause</u>.&#160; The Company may terminate the Executive&#8217;s employment at any time for Cause upon written notice to the
      Executive, in which event all payments under this Agreement shall cease, except for any Accrued Obligations.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">9.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Voluntary Resignation Without Good Reason</u>.&#160; The Executive may voluntarily terminate employment without Good
      Reason upon 30 days&#8217; prior written notice to the Company.&#160; In such event, after the effective date of such termination, no payments shall be due under this Agreement, except that the Executive shall be entitled to any Accrued Obligations.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">10.<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160; </font><u>Disability</u>.&#160; If the Executive incurs a Disability during the Term, the Company may terminate the Executive&#8217;s
      employment on or after the date of Disability.&#160; If the Executive&#8217;s employment terminates on account of Disability, the Executive shall be entitled to receive any Accrued Obligations and if the Executive executes and does not revoke the Release, an
      amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination for Disability; provided, that such termination occurs six months or more into the applicable
      performance period.&#160; For purposes of this Agreement, the term &#8220;<u>Disability</u>&#8221; shall mean the Executive is eligible to receive long-term disability benefits under the Company&#8217;s long-term disability plan and if the Company does not have a long-term
      disability plan, shall mean the Executive&#8217;s inability, due to physical or mental incapacity, to perform the essential functions of Executive&#8217;s position, with or without reasonable accommodation, for 120 days out of any 365 day period.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">11.<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font><u>Death</u>.&#160; If the Executive dies during the Term, the Executive&#8217;s employment shall terminate on the date of death
      and the Company shall pay to the Executive&#8217;s executor, legal representative, administrator or designated beneficiary, as applicable, any Accrued Obligations.&#160; The Company shall have no further liability or obligation under this Agreement to the
      Executive&#8217;s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through the Executive.</div>
    <div>&#160;</div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal;">12.<font style="font-family: 'Times New Roman', Times, serif;"><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Resignation of Positions</font>.&#160; Effective as of the date of any termination of employment, the Executive will resign from all Company-related positions, including as an officer and director of
        the Company and its parent(s), subsidiaries, and Affiliates.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify;">13.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Definitions</u>.&#160; For purposes of this Agreement, the following terms shall have the following meanings:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#8220;<u>Accrued Obligations</u>&#8221; shall mean (i)&#160;any Base Salary earned through the Executive&#8217;s
      termination of employment that remains unpaid; (ii) any Annual Bonus payable with respect to any calendar year which ended prior to the effective date of the Executive&#8217;s termination of employment, which remains unpaid; (iii) in the event of a
      termination of employment as a result of death, an amount equal to the Target Annual Bonus, prorated for the portion of the performance period that the Executive was employed prior to such termination; provided, that such termination occurs six
      months or more into the applicable performance period for such Annual Bonus; or (iv) any accrued, unused personal time off days, if required to be paid out under the Company policies.&#160; The Accrued Obligations shall be paid following the Executive&#8217;s
      termination of employment at such times and in accordance with such policies as would normally apply to such amounts and regardless of whether the Executive executes or revokes the Release.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(b)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#8220;<u>Cause</u>&#8221; shall mean any of the following grounds for the Executive&#8217;s termination of employment
      listed: (i) the Executive&#8217;s knowing and material dishonesty or fraud committed in connection with the Executive&#8217;s employment; (ii) theft, misappropriation, or embezzlement by the Executive of the Company&#8217;s funds; (iii) the Executive repeatedly
      negligently performing or failing to perform, or willfully refusing to perform, the Executive&#8217;s duties to the Company (other than a failure resulting from Executive&#8217;s incapacity due to physical or mental illness); (iv) the Executive&#8217;s conviction of
      or a plea of guilty or <font style="font-style: italic;">nolo contendere</font> to any felony, a crime involving fraud or misrepresentation, or any other crime (whether or not connected with his employment) the effect of which is likely to adversely
      affect the Company or its Affiliates; (v) <font style="color: #000000;">a material breach by the Executive of any of the provisions or covenants set forth in this Agreement; (vi) a material breach by the Executive of the Company&#8217;s Code of Conduct
        and Business Ethics; or (vii) any other act or omission by the Executive that has a material adverse effect on the Company&#8217;s ability to operate.&#160; </font>Prior to any termination of employment for Cause pursuant to each such event listed in (i),
      (iii), (v), (vi), or (vii) above, to the extent such event(s) is capable of being cured by the Executive, the Company shall give the Executive written notice thereof describing in reasonable detail the circumstances constituting Cause and the
      Executive shall have the opportunity to remedy same within thirty (30) days after receiving written notice.&#160; If the circumstances alleged to constitute Cause are remedied within the thirty (30) day cure period, no Cause shall exist to terminate
      Executive.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(c)</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#8220;<u>Change in Control</u>&#8221; shall have the meaning set forth in
      the Equity Plan.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(d)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#8220;<u>Change in Control Period</u>&#8221; shall mean the period commencing 90 days prior to a Change in
      Control and ending on the first anniversary of such Change in Control.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(e)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#8220;<u>CIC Termination</u>&#8221; shall mean termination of the Executive&#8217;s employment by the Company without
      Cause or by the Executive for Good Reason during the Change in Control Period, provided that, in either case, a Change in Control actually occurs.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(f)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#8220;<u>Good Reason</u>&#8221; shall mean the occurrence of one or more of the following without the
      Executive&#8217;s consent, other than on account of the Executive&#8217;s Disability:</div>
    <div>&#160;</div>
    <div style="text-indent: 108pt;">(i)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>A material diminution by the Company of the Executive&#8217;s, title authority, reporting structure, duties or
      responsibilities;</div>
    <div>&#160;</div>
    <div style="text-indent: 108pt;">(ii)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>A material change in the geographic location at which the Executive must perform services under this Agreement (which,
      for purposes of this Agreement, means relocation of the Executive&#8217;s Principal Place of Employment to a location that increases the Executive&#8217;s commute to work by more than 35 miles);</div>
    <div>&#160;</div>
    <div style="text-indent: 108pt;">(iii)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>A reduction in the Executive&#8217;s Base Salary (other than an across the board reduction of base salary for similarly
      situated senior level executives); or</div>
    <div>&#160;</div>
    <div style="text-indent: 108pt;">(iv)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Any action or inaction that constitutes a material breach by the Company of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">The Executive must provide written notice of termination for Good Reason to the Company within 60 days after the event constituting Good Reason.&#160; The Company shall have a period of 30 days in which
      it may correct the act or failure to act that constitutes the grounds for Good Reason as set forth in the Executive&#8217;s notice of termination.&#160; If the Company does not correct the act or failure to act, the Executive&#8217;s employment will terminate for
      Good Reason on the first business day following the Company&#8217;s 30-day cure period.</div>
    <div>&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif;">(g)</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<u>Release</u>&#8221; shall mean a separation agreement and general release of any and all claims against the Company and its Affiliates with respect to all matters arising out of the Executive&#8217;s employment by the Company, and
        the termination thereof (other than claims for any entitlements under the terms of this Agreement or under any plans or programs of the Company under which the Executive has accrued and is due a benefit).&#160; The Release will be in form and substance
        specified by and acceptable to the Company and Executive, and will include provisions in which the Executive shall reaffirm and agree to remain bound by the restrictive covenants set forth in Section 15 below. Such general release shall be executed
        and delivered (and no longer subject to the 7 business day revocation period) by the Executive within sixty (60) days following delivery of the general release to the Executive.</font> <br>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">14.<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font><u>Section 409A</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>This Agreement is intended to comply with section 409A of the Internal Revenue Code of 1986, as
      amended (the &#8220;<u>Code</u>&#8221;), and its corresponding regulations, or an exemption thereto, and payments may only be made under this Agreement upon an event and in a manner permitted by section 409A of the Code, to the extent applicable.&#160; Severance
      benefits under this Agreement are intended to be exempt from section 409A of the Code under the &#8220;short-term deferral&#8221; exception, to the maximum extent applicable, and then under the &#8220;separation pay&#8221;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">exception, to the maximum extent applicable.&#160; Notwithstanding anything in this Agreement to the contrary, if required by section 409A of the Code, if the Executive is considered a &#8220;specified employee&#8221; for purposes of
      section 409A of the Code and if payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to section 409A of the Code, payment of such amounts shall be delayed as required
      by section 409A of the Code, and the accumulated amounts shall be paid in a lump-sum payment within 10 days after the end of the six-month period.&#160; If the Executive dies during the postponement period prior to the payment of benefits, the amounts
      withheld on account of section 409A of the Code shall be paid to the personal representative of the Executive&#8217;s estate within 60 days after the date of the Executive&#8217;s death.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>All payments to be made upon a termination of employment under this Agreement may only be made upon
      a &#8220;separation from service&#8221; under section 409A of the Code.&#160; For purposes of section 409A of the Code, each payment hereunder shall be treated as a separate payment, and the right to a series of installment payments under this Agreement shall be
      treated as a right to a series of separate payments.&#160; In no event may the Executive, directly or indirectly, <font style="color: #000000;">designate the fiscal year of a payment.&#160; </font>Notwithstanding any provision of this Agreement to the
      contrary, in no event shall the timing of the Executive&#8217;s execution of the Release, directly or indirectly, result in the Executive&#8217;s designating the fiscal year of payment of any amounts of deferred compensation subject to section 409A of the Code,
      and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: #000000;">(c)</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>All reimbursements and in-kind benefits provided under this
      Agreement shall be made or provided in accordance with the requirements of section 409A of the Code,<font style="color: #000000;"> including, where applicable, the requirement that (i) any reimbursement be for expenses incurred during the period
        specified in this Agreement, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a fiscal year not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other fiscal
        year, (iii) the reimbursement of an eligible expense be made no later than the last day of the fiscal year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits not be subject to liquidation or
        exchange for another benefit.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify;">15.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Restrictive Covenants</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Noncompetition</u>.&#160; The Executive agrees that during the Executive&#8217;s employment with the Company
      and its Affiliates and (i) the number of months in the CIC Severance Term after a CIC Termination and (ii) for any other termination of employment, including a termination of employment where severance is not payable to the Executive, twelve months
      (the &#8220;<u>Restriction Period</u>&#8221;), the Executive will not, without the Board&#8217;s express written consent, engage (directly or indirectly) in any Competitive Business in the United States or Canada.&#160; The term &#8220;<u>Competitive Business</u>&#8221; means any
      person, concern or entity which is engaged in or conducts a business substantially the same as the Business of the Company and its Affiliates. The term &#8220;<u>Business</u>&#8221; means the discovery, research, development and commercialization by the Company
      or its Affiliates of gene therapy treatments currently under active discovery, development or commercialization (generally referred to internally as &#8220;Programs&#8221; and &#8220;Pipeline&#8221;), including material external sponsored research agreements. The Executive
      understands and agrees that, given the nature of the business of the Company and its Affiliates and the Executive&#8217;s position with the Company, the foregoing scope is reasonable and appropriate, and necessary to protect the</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">Company&#8217;s legitimate business interests.&#160; For purposes of this Agreement, the term &#8220;<u>Affiliate</u>&#8221; means any subsidiary of the Company or Parent or any other entity under common control with the Company.&#160; The
      Executive and the Company agree that the terms set forth in this Agreement, including without limitation, the increase in Base Salary, the Annual Bonus opportunity and severance rights that the Company is awarding the Executive as consideration for
      the covenants in this Section 15(a) is mutually-agreed upon consideration for the Executive&#8217;s compliance with this Section 15(a).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Nonsolicitation of Company Personnel</u>.&#160; The Executive agrees that during the Restriction
      Period, the Executive will not, either directly or through others, hire or attempt to hire any employee of the Company or its Affiliates, or solicit or attempt to solicit any such person to change or terminate his or her relationship with the Company
      or an Affiliate or otherwise to become an employee, consultant or independent contractor to, for or of any other person or business entity; provided that the foregoing does not prohibit general solicitation or recruitment activities not directed at
      employees of the Company or soliciting, recruiting or hiring any person who responds thereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><u>Nonsolicitation of Customers</u>.&#160; The Executive agrees that during the Restriction Period, the
      Executive will not, either directly or through others, solicit, divert or appropriate, or attempt to solicit, divert or appropriate, any customer of the Company or an Affiliate for the purpose of providing such customer&#160; with services or products
      competitive with those offered by the Company or an Affiliate during the Executive&#8217;s employment with the Company or an Affiliate.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><u>Proprietary Information</u>.&#160; At all times, the Executive will hold in strictest confidence and
      will not disclose, use, lecture upon or publish any of the Proprietary Information (defined below) of the Company or an Affiliate, except as such disclosure, use or publication may be required in connection with the Executive&#8217;s work for the Company
      or as described in Section 15(e) below, or unless the Company expressly authorizes such disclosure in writing.&#160; &#8220;<u>Proprietary Information</u>&#8221; shall mean any and all confidential and/or proprietary knowledge, data or information of the Company and
      its Affiliates and shareholders, including but not limited to information relating to financial matters, investments, budgets, business plans, marketing plans, personnel matters, business contacts, products, processes, know-how, designs, methods,
      improvements, discoveries, inventions, ideas, data, programs, and other works of authorship.&#160; For purposes of this Agreement, the term &#8220;<u>Proprietary Information</u>&#8221; shall not include information which is or becomes publicly available without
      breach of: (i) this Agreement; (ii) any other agreement or instrument to which the Company or an Affiliate is a party or a beneficiary; or (iii) any duty owed to the Company or an Affiliate by the Executive or by any third party.&#160; It shall also not
      include any information that was reasonably demonstrated to be known to Executive prior to Executive&#8217;s employment with the Company; <font style="font-style: italic;"><u>provided</u></font>, <font style="font-style: italic;"><u>however</u></font>,
      that if the Executive shall desire or seek to disclose, use, lecture upon, or publish any Proprietary Information, the Executive shall first obtain approval from the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Reports to Government Entities</u>.&#160; Nothing in this Agreement shall prohibit or restrict the
      Executive from initiating communications directly with, responding to any inquiry from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or filing a claim or assisting with an
      investigation directly with a self-regulatory authority or a government agency or entity, including the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">Department of Justice, the Securities and Exchange Commission, Congress, any agency Inspector General or any other federal, state or local regulatory authority (collectively, the &#8220;<u>Regulators</u>&#8221;), or from making
      other disclosures that are protected under the whistleblower provisions of state or federal law or regulation.&#160; The Executive does not need the prior authorization of the Company to engage in conduct protected by this subsection, and the Executive
      does not need to notify the Company that the Executive has engaged in such conduct.&#160; Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose
      trade secrets to their attorneys, courts, or government officials in certain, confidential circumstances that are set forth at 18 U.S.C. &#167;&#167; 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or
      in connection with a lawsuit for retaliation for reporting a suspected violation of the law.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f)<font style="color: #000000;"><u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Inventions Assignment</u>.&#160; The Executive agrees that all
        inventions, innovations, improvements, developments, methods, designs, analyses, rep</font>orts, and all related information which relates to the Company&#8217;s or its Affiliates&#8217; actual&#160; business, research and development of existing or future products
      or services and which are&#160; actually being developed or made by the Executive while employed by the Company, on Company time and using Company resources (&#8220;<u>Work Product</u>&#8221;) belong to the Company.&#160; The Executive will perform all actions reasonably
      requested by the Board (whether during or after the Term) to establish and confirm such ownership (including, without limitation, assignments, consents, limited powers of attorney and other instruments).&#160; If requested by the Company, the Executive
      agrees to execute any inventions assignment and confidentiality agreement that is required to be signed by Company employees generally.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(g)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><u>Return of Company Property</u><font style="font-variant: small-caps;">.</font>&#160; Within a
      reasonable time after termination of the Executive&#8217;s employment with the Company for any reason, and at any earlier time the Company requests, the Executive will deliver to the person designated by the Company all originals and copies of all
      documents and property of the Company or an Affiliate that is in the Executive&#8217;s possession or under the Executive&#8217;s control or to which the Executive may have access.&#160; The Executive will not reproduce or appropriate for the Executive&#8217;s own use, or
      for the use of others, any property, proprietary information, or Work Product.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(h)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font><u>Restrictive Covenant Acknowledgement</u>.&#160; The Executive acknowledges and agrees that the
      foregoing restrictions contained in Section 15 are reasonable, proper and necessitated by the legitimate business interests of the Company and will not prevent the Executive from earning a living or pursuing a career. In the event that a court of
      competent jurisdiction determines that any of the provisions of this Agreement (including, without limitation, the provisions of Section 15) would be unenforceable as written because they cover too extensive a geographic area, too broad a range of
      activities, too long a period of time, insufficient consideration, or otherwise, then such provisions automatically shall be modified to cover the maximum geographic area, range of activities, and period of time as may be enforceable, and the minimum
      amount of required consideration as may be enforceable, and in addition, such court is hereby expressly authorized so to modify this Agreement and to enforce it as so modified.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">16.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Legal and Equitable Remedies</u>.&#160; Because the Executive&#8217;s services are personal and unique and the Executive has
      had and will continue to have access to and has become and will continue to become acquainted with the proprietary information of the Company and its Affiliates, and because any breach by the Executive of any of the restrictive covenants contained in
      Section 15</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">would result in irreparable injury and damage for which money damages would not provide an adequate remedy, the Company shall have the right to seek to enforce Section 15 and any of its provisions by injunction,
      specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach, or threatened breach, of the restrictive covenants set forth in Section 15.&#160; </div>
    <div>&#160;</div>
    <div style="text-align: justify;">17.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Survival</u>.&#160; The respective rights and obligations of the parties under this Agreement (including, but not
      limited to, under Sections 15 and 16) shall survive any termination of the Executive&#8217;s employment or termination or expiration of this Agreement to the extent necessary to the intended preservation of such rights and obligations.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">18.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>No Mitigation or Set-Off</u>.&#160; In no event shall the Executive be obligated to seek other employment or take any
      other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, and such amounts shall not be reduced regardless of whether the Executive obtains other employment.&#160; The Company&#8217;s obligation to
      make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including, without limitation, any set-off, counterclaim, recoupment, defense or other right which the
      Company may have against the Executive or others.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">19.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Section 280G</u>.&#160; In the event of a change in ownership or control under section 280G of the Code, if it shall be
      determined that any payment or distribution in the nature of compensation (within the meaning of section 280G(b)(2) of the Code) to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of
      this Agreement or otherwise (a &#8220;<u>Payment</u>&#8221;), would constitute an &#8220;excess parachute payment&#8221; within the meaning of section 280G of the Code, the aggregate present value of the Payments under this Agreement shall be reduced (but not below zero) to
      the Reduced Amount (defined below) if and only if the Accounting Firm (described below) determines that the reduction will provide the Executive with a greater net after-tax benefit than would no reduction.&#160; No reduction shall be made unless the
      reduction would provide Executive with a greater net after-tax benefit.&#160; The determinations under this Section shall be made as follows:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>The &#8220;<u>Reduced Amount</u>&#8221; shall be an amount expressed in present value which maximizes the
      aggregate present value of Payments under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax (defined below), determined in accordance with section 280G(d)(4) of the Code.&#160; The term &#8220;<u>Excise Tax</u>&#8221;
      means the excise tax imposed under section 4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>Payments under this Agreement shall be reduced on a nondiscretionary basis in such a way as to
      minimize the reduction in the economic value deliverable to the Executive.&#160; Where more than one payment has the same value for this purpose and they are payable at different times, they will be reduced on a pro rata basis.&#160; Only amounts payable under
      this Agreement shall be reduced pursuant to this Section.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>All determinations to be made under this Section shall be made by an independent certified public
      accounting firm selected by the Company and agreed to by the Executive immediately prior to the change-in-ownership or -control transaction (the &#8220;<u>Accounting Firm</u>&#8221;).&#160; The Accounting Firm shall provide its determinations and any supporting
      calculations both to the Company and the Executive within 10 days of the transaction.&#160; Any such determination by the</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">Accounting Firm shall be binding upon the Company and the Executive.&#160; All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section shall be borne solely by the
      Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">20.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Tax </u><u>Equalization</u>.&#160; The Company will reimburse the Executive for all reasonable and necessary costs
      incurred in connection with any cross-border tax filings that may be required, as well as the cost of joining the NEXUS program and any other visa or related issues with respect to the Executive&#8217;s employment with the Company. To the extent the
      Executive is subject to additional taxes in respect of services performed in Canada (whenever such services were performed on the Company&#8217;s behalf), the Company will reimburse the Executive for such additional taxes with an appropriate gross up
      calculation such that the Executive pays no more income taxes in respect of compensation from the Company then the Executive would have paid had the services solely been performed in the United States.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">21.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Notices</u>.&#160; All notices and other communications required or permitted under this Agreement or necessary or
      convenient in connection herewith shall be in writing and shall be deemed to have been given when emailed, hand delivered or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when
      received):</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">If to the Company, to:</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 72pt;">177 Huntington Avenue</div>
    <div style="text-align: justify; margin-left: 72pt;">Suite 1703 PMB 97584</div>
    <div style="text-align: justify; margin-left: 72pt;">Boston, MA 02115-3153</div>
    <div style="text-align: justify; margin-left: 72pt;">Attn: Chief Executive Officer</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">If to the Executive, to the most recent address on file with the Company or to such other names or addresses as the Company or the Executive, as the case may be, shall designate by notice to each
      other person entitled to receive notices in the manner specified in this Section.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">22.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Withholding</u>.&#160; All payments under this Agreement shall be made subject to applicable tax withholding, and the
      Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation.&#160; The Executive shall bear all expense of, and be solely
      responsible for, all federal, state and local taxes due with respect to any payment received under this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">23.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Remedies Cumulative; No Waiver</u>.&#160; No remedy conferred upon a party by this Agreement is intended to be exclusive
      of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity.&#160; No delay or omission by a party in exercising any
      right, remedy or power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be deemed expedient or
      necessary by such party in its sole discretion.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">24.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Binding Arbitration and Waiver of Right to Participate in Class Actions</u>.&#160; Except for disputes relating to, or
      arising out of, the Executive&#8217;s obligations set forth in Section 15, including the Company&#8217;s right to independently seek and obtain injunctive relief in state or federal courts, the parties agree to arbitrate any and all claims, disputes or
      controversies relating to, or arising out of, or concerning, this Agreement and/or the Executive&#8217;s employment with the Company, including termination of the Executive&#8217;s employment.&#160; The parties&#8217; agreement to arbitrate</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">employment-related claims is intended to include, but is not limited to, claims concerning compensation, benefits or other terms and conditions of employment, or any other claims whether arising by statute or otherwise
      including, but not limited to, employment claims of wrongful discharge, discrimination, harassment or retaliation under federal, state or local laws including, without limitation, Commonwealth of Massachusetts; Title VII of the Civil Rights Act as
      amended, the Equal Pay Act, the Americans With Disabilities Act (as amended), the Age Discrimination in Employment Act, the Older Workers Benefits Protection Act; the Patient Protection and Affordable Care Act, and claims arising under the Fair Labor
      Standards Acts, or any other national, federal, state or local employment or discrimination laws, rules or regulations.&#160; The Executive&#8217;s agreement to arbitrate also includes claims for breach of contract, violation of internal procedure or policy,
      wrongful termination in violation of public policy, wrongful discharge or termination, tort claims including negligence, defamation, loss of reputation, interference with contractual relations or prospective economic advantage, retaliation, and
      negligent or intentional infliction of emotional distress.&#160; The Executive agrees that all such claims will be fully and finally resolved by mandatory, binding arbitration conducted by the American Arbitration Association (&#8220;AAA&#8221;) located within thirty
      miles of the Executive&#8217;s Principal Place of Employment, pursuant to the AAA then-current Employment Arbitration Rules and Mediation Procedures.&#160; A copy of those rules is available online at www.adr.org/aaa. The Company as the employer will bear the
      administrative costs and arbitrator fees, and the arbitrator in such action may award whatever remedies would be available to the parties in a court of law.&#160; The purpose of this provision is to require binding arbitration of such disputes, claims or
      controversies that are or may be arbitrable, and the inclusion of any claim in this provision as to which a jury trial or civil action may not be waived will not taint or invalidate the remainder of this provision.&#160; To be clear, this agreement to
      arbitrate does not apply to any lawsuit to enforce this arbitration clause, or, as referenced above, to seek relief as set forth in Section 15 of this Agreement.&#160; Those lawsuits will be commenced in the state or federal courts sitting in the
      Commonwealth of Massachusetts and the Executive consents to the jurisdiction of the federal or state courts of Massachusetts.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">25.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Assignment</u>.&#160; All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit
      of and be enforceable by the respective heirs, executors, administrators, legal representatives, successors and assigns of the parties hereto, except that the duties and responsibilities of the Executive under this Agreement are of a personal nature
      and shall not be assignable or delegable in whole or in part by the Executive.&#160; The Company may assign its rights, together with its obligations hereunder, in connection with any sale, transfer or other disposition of all or substantially all of its
      business and assets, and such rights and obligations shall inure to, and be binding upon, any successor to the business or any successor to substantially all of the assets of the Company, whether by merger, purchase of stock or assets or otherwise,
      which successor shall expressly assume such obligations, and the Executive acknowledges that in such event the obligations of the Executive hereunder, including but not limited to those under Section 15, will continue to apply in favor of the
      successor.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">26.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Company Policies</u>.&#160; This Agreement and the compensation payable hereunder shall be subject to any applicable
      clawback or recoupment policies, share trading policies, and other policies that may be implemented by the Board from time to time with respect to officers of the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">27.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Indemnification</u>.&#160; In the event the Executive is made, or threatened to be made, a party to any legal action or
      proceeding, whether civil or criminal, including any governmental or regulatory</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">proceedings or investigations, by reason of the fact that the Executive is or was a director or officer of the Company or any of its Affiliates, the Executive shall be fully indemnified by the Company, and the Company
      shall pay the Executive&#8217;s related expenses (including reasonable attorneys&#8217; fees, judgments, fines, settlements and other amounts incurred in connection with any proceeding arising out of) when and as incurred, to the fullest extent permitted by
      applicable law and the Company&#8217;s articles of incorporation and bylaws.&#160; During the Executive&#8217;s employment with the Company or any of its Affiliates and after termination of employment for any reason, the Company shall cover the Executive under the
      Company&#8217;s directors&#8217; and officers&#8217; insurance policy applicable to other officers and directors according to the terms of such policy.&#160; Such obligations shall be binding upon the Company&#8217;s successors and assigns and shall inure to the benefit of the
      Executive&#8217;s heirs and personal representatives.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">28.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Entire Agreement</u>.&#160; This Agreement sets forth the entire agreement of the parties related to the items set forth
      herein and supersedes any and all prior agreements and understandings related thereto, including without limitation the employment letter agreement with the Company dated August 31, 2023.&#160; This Agreement may be changed only by a written document
      signed by the Executive and the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">29.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Severability</u>.&#160; If any provision of this Agreement or application thereof to anyone or under any circumstances
      is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of this Agreement, which can be given effect without the invalid or unenforceable provision or
      application, and shall not invalidate or render unenforceable such provision or application in any other jurisdiction.&#160; If any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in
      full force and effect in all other circumstances.</div>
    <div>&#160;</div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal;">30.<font style="font-family: 'Times New Roman', Times, serif;"><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Governing Law</font>.&#160; This Agreement shall be governed by, and construed and enforced in accordance with, the substantive and procedural laws of the Commonwealth of Massachusetts without regard
        to rules governing conflicts of law.&#160; </font></div>
    <div>&#160;</div>
    <div style="text-align: justify;">31.<u><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font>Counterparts</u>.&#160; This Agreement may be executed in any number of counterparts (including facsimile counterparts),
      each of which shall be an original, but all of which together shall constitute one instrument.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">32.<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;</font><u>Acknowledgments</u>.&#160; The Executive acknowledges that (a) the Executive has the right to consult with counsel prior
      to signing this Agreement and has had a full and adequate opportunity to read, understand and discuss with the Executive&#8217;s advisors, including counsel, the terms and conditions contained in this Agreement prior to signing hereunder, (b) this
      Agreement is supported by fair and reasonable consideration independent from the continuation of employment, and (c) the Executive received notice of this Agreement at least ten business days before it is to be effective.</div>
    <div>&#160;</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">(Signature Page Follows)</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z92bb791ea80e4af2b1163239f963c840">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">ENGENE USA, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="border-bottom: 1px solid #000000; vertical-align: top; width: 50%;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Jason D. Hanson</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Name:&#160; Jason D. Hanson</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Title:&#160; Chief Executive Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Date: November 29, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">EXECUTIVE</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="border-bottom: 1px solid #000000; vertical-align: top; width: 50%;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Richard Bryce</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Name: Dr. Richard Bryce</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Date:&#160; November 29, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify;"><br>
    </div>
    <div>&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>exhibit99-1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Morgan Lewis
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">EXHIBIT 99.1</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">enGene Appoints Ryan Daws as Chief Financial Officer</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold; color: #000000;">Boston, Mass. and Montreal, Canada,
        November 29, 2023 </font>&#8212; enGene Holdings Inc. (&#8220;enGene,&#8221; Nasdaq: ENGN, ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced
      the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">&#8220;I am delighted to welcome Ryan to enGene at a critical time in our growth, as we move forward as a public company and work to advance our ongoing
      pivotal-stage EG-70 clinical study in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC),&#8221; said Jason D. Hanson, Chief Executive Officer of enGene. &#8220;Ryan&#8217;s significant experience across multiple areas of financial, business development and
      operational management in the pharmaceutical industry, as well as healthcare investment banking, complements our leadership team. We look forward to working with Ryan to continue to serve our shareholders, clinicians, and ultimately patients, in
      pursuit of our longstanding goal of mainstreaming gene therapy and bringing our genetic medicines to community clinics across the globe.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Mr. Daws joins enGene with nearly 25 years of life sciences-focused operational and deal-making experience. Prior to joining enGene, Mr. Daws was Chief
      Financial Officer and Head of Business Development at Obsidian Therapeutics, Inc.&#160; In that role, he was responsible for finance, business development, information technology, investor relations and facilities functions. Prior to joining Obsidian
      Therapeutics, Mr. Daws was Managing Director with the Healthcare Investment Banking Group at Robert W. Baird &amp; Co., Inc. where he was responsible for IPOs, follow-on offerings, private placements and mergers and acquisition transactions in the
      life sciences sector. Mr. Daws also previously served as Chief Financial Officer and Head of Business Development at Concert Pharmaceuticals, Inc.&#160; Prior to Concert Pharmaceuticals, Mr. Daws spent nearly 15 years originating and executing equity and
      mergers and acquisitions transactions in the life sciences sector, first at Cowen and Company, LLC and then Stifel, Nicolaus &amp; Co, Inc. Mr. Daws earned his International Master of Business Administration and Bachelor of Science in Business
      Administration from the University of South Carolina.<br>
      <br>
      Mr. Daws commented, &#8220;This is an exciting time to join enGene, with our pivotal clinical study in BCG-unresponsive NMIBC actively enrolling patients and progressing towards our anticipated interim data read-out in mid-2024. We have a compelling
      opportunity to advance a new era of genetic medicines to reach larger patient populations, and I look forward to working alongside the team in furtherance of our mission.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">About enGene</div>
    <div style="text-align: justify;">enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs,
      with the goal of creating new ways to address diseases with high clinical needs. enGene&#8217;s lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or na&#239;ve to treatment with
      Bacillus Calmette-Gu&#233;rin (BCG) - a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene&#8217;s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables
      penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. enGene became a publicly traded company effective November 1, 2023, upon the completion of a business combination with
      Forbion European Acquisition Corporation, a special purpose acquisition company. For more information, visit enGene.com.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify; font-weight: bold;"><u>Forward-Looking Statements</u></div>
    <div><br>
    </div>
    <div style="text-align: justify;">Some of the statements contained in this press release may constitute forward-looking statements within the meaning of the safe harbor provisions of the
      Private Securities Litigation Reform Act of 1995, and &#8220;forward-looking information&#8221; within the meaning of Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).&#160; enGene&#8217;s forward-looking statements include, but are not limited to,
      statements regarding enGene&#8217;s expectations, hopes, beliefs, intentions, goals, strategies, forecasts and projections. The words &#8220;anticipate&#8221;, &#8220;appear&#8221;, &#8220;approximate&#8221;, &#8220;believe&#8221;, &#8220;continue&#8221;, &#8220;could&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;foresee&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;,
      &#8220;might&#8221;, &#8220;plan&#8221;, &#8220;possible&#8221;, &#8220;potential&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;seek&#8221;, &#8220;should&#8221;, &#8220;would&#8221;, and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
      Forward-looking statements may include, for example, statements about: enGene&#8217;s goal of mainstreaming gene therapy and bringing genetic medicines</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">to community clinics across the globe and the expected timeline for the interim Phase 2 results from the EG-70 program.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Many factors, risks, uncertainties and assumptions could cause the Company&#8217;s actual results, performance or achievements to differ materially from those
      expressed or implied by the forward-looking statements, including, without limitation, the Company&#8217;s ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical
      trials and acquire technologies complimentary to, or necessary for, its programs; the Company&#8217;s ability to address diseases with high clinical needs; the Company&#8217;s ability to retain commercial rights to EG-70 in the United States and commercialize
      EG-70 independently, while selectively partnering outside of the United States; the Company&#8217;s plans and ability to secure regulatory approval, to execute product development, manufacturing process development, preclinical and clinical development
      efforts successfully and on anticipated timelines; enGene&#8217;s ability to design mainstream gene therapy and bring genetic medicines to community clinics across the globe; and other risks and uncertainties detailed in filings with Canadian securities
      regulators on SEDAR+ and with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on EDGAR, including those described in the &#8220;Risk Factors&#8221; section of the Registration Statement on Form S-1 filed by the Company with the SEC on November 21, 2023
      (copies of which may be obtained at <font style="color: #0070C0;"><u>sedarplus.ca</u>&#160;</font>or
      <font style="color: #0070C0;"><u>www.sec.gov</u></font>).</div>
    <div><br>
    </div>
    <div style="text-align: justify;">You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that
      subsequent events and developments will cause enGene&#8217;s assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by
      applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will
      be achieved.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Contact:</div>
    <div><br>
    </div>
    <div>For further information: enGene, Inc. (<u><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 255);">media@engene.com</font></u>).</div>
    <div>For investor contact: <u><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 255);">investors@engene.com</font></u></div>
    <div>For media contact: <u><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 255);">Adam@ScientPR.com</font></u></div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>engn-20231127.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<xs:schema targetNamespace="http://engene.com/20231127" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:engn="http://engene.com/20231127" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="engn-20231127_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="engn-20231127_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="engn-20231127_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://engene.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:element name="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" id="engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonsharesMember" id="engn_CommonsharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>engn-20231127_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://engene.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="engn-20231127.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://engene.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="definition: EntityListingsLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="definition: EntityListingsLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: EntityListingsLineItems to DocumentPeriodEndDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalYearFocus" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="definition: EntityListingsLineItems to EntityFileNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: EntityListingsLineItems to EntityRegistrantName" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: EntityListingsLineItems to EntityCentralIndexKey" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: EntityListingsLineItems to EntityTaxIdentificationNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine2" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="definition: EntityListingsLineItems to EntityAddressAddressLine3" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: EntityListingsLineItems to EntityAddressCityOrTown" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: EntityListingsLineItems to EntityAddressStateOrProvince" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="definition: EntityListingsLineItems to EntityAddressCountry" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: EntityListingsLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="definition: EntityListingsLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: EntityListingsLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="definition: EntityListingsLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="definition: EntityListingsLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="definition: EntityListingsLineItems to NoTradingSymbolFlag" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: EntityListingsLineItems to SecurityExchangeName" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: EntityListingsLineItems to EntityEmergingGrowthCompany" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="EntityExTransitionPeriod" xlink:title="definition: EntityListingsLineItems to EntityExTransitionPeriod" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="definition: EntityListingsLineItems to WrittenCommunications" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="definition: EntityListingsLineItems to SolicitingMaterial" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementTenderOffer" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="definition: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityListingsLineItems" xlink:to="EntityListingsTable" xlink:title="definition: EntityListingsLineItems to EntityListingsTable" order="30.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: EntityListingsTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="engn-20231127.xsd#engn_CommonsharesMember" xlink:label="CommonsharesMember" xlink:title="CommonsharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonsharesMember" xlink:title="definition: ClassOfStockDomain to CommonsharesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="engn-20231127.xsd#engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:label="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:title="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:title="definition: ClassOfStockDomain to WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>engn-20231127_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:label xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="dei_EntityExTransitionPeriod_lbl">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:title="label: EntityExTransitionPeriod to dei_EntityExTransitionPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsTable_lbl" xml:lang="en-US" id="dei_EntityListingsTable_lbl">Entity Listings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsTable" xlink:to="dei_EntityListingsTable_lbl" xlink:title="label: EntityListingsTable to dei_EntityListingsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_EntityListingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityListingsLineItems_lbl" xml:lang="en-US" id="dei_EntityListingsLineItems_lbl">Entity Listings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:title="label: EntityListingsLineItems to dei_EntityListingsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="engn-20231127.xsd#engn_CommonsharesMember" xlink:label="CommonsharesMember" xlink:title="CommonsharesMember" />
    <link:label xlink:type="resource" xlink:label="engn_CommonsharesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="engn_CommonsharesMember_lbl1" xml:lang="en-US" id="engn_CommonsharesMember_lbl1">Commonshares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonsharesMember" xlink:to="engn_CommonsharesMember_lbl1" xlink:title="label: CommonsharesMember to engn_CommonsharesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="engn-20231127.xsd#engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:label="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:title="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" />
    <link:label xlink:type="resource" xlink:label="engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember_lbl1" xml:lang="en-US" id="engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember_lbl1">Warrants, each exercisable for one Common common share, at an exercise price of $11.50 per share [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:to="engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember_lbl1" xlink:title="label: WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember to engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>engn-20231127_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://engene.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="engn-20231127.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://engene.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsTable" xlink:label="EntityListingsTable" xlink:title="EntityListingsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="engn-20231127.xsd#engn_CommonsharesMember" xlink:label="CommonsharesMember" xlink:title="CommonsharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonsharesMember" xlink:title="presentation: ClassOfStockDomain to CommonsharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="engn-20231127.xsd#engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:label="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:title="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" xlink:title="presentation: ClassOfStockDomain to WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: EntityListingsTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsLineItems" xlink:label="EntityListingsLineItems" xlink:title="EntityListingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentType" xlink:title="presentation: EntityListingsLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: EntityListingsLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: EntityListingsLineItems to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: EntityListingsLineItems to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: EntityListingsLineItems to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: EntityListingsLineItems to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: EntityListingsLineItems to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: EntityListingsLineItems to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: EntityListingsLineItems to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: EntityListingsLineItems to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: EntityListingsLineItems to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: EntityListingsLineItems to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressCountry" xlink:title="presentation: EntityListingsLineItems to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: EntityListingsLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="CityAreaCode" xlink:title="presentation: EntityListingsLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: EntityListingsLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="Security12bTitle" xlink:title="presentation: EntityListingsLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="TradingSymbol" xlink:title="presentation: EntityListingsLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: EntityListingsLineItems to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: EntityListingsLineItems to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: EntityListingsLineItems to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="EntityExTransitionPeriod" xlink:title="presentation: EntityListingsLineItems to EntityExTransitionPeriod" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="WrittenCommunications" xlink:title="presentation: EntityListingsLineItems to WrittenCommunications" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="SolicitingMaterial" xlink:title="presentation: EntityListingsLineItems to SolicitingMaterial" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsLineItems" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: EntityListingsLineItems to PreCommencementIssuerTenderOffer" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityListingsTable" xlink:to="EntityListingsLineItems" xlink:title="presentation: EntityListingsTable to EntityListingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityListingsTable" xlink:title="presentation: CoverAbstract to EntityListingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>engene_logo.jpg
<TEXT>
begin 644 engene_logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 10#= P$1  (1 0,1 ?_$ +    (" 04! 0
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MKNT5EA)(P[ZQ03*7<=/MXIW+L&TDOU@!B^BQ6<$=*=11 0V(.X: [L#%,)@
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M ,4_'BY%V,6KS+^6\>8Q:J%(JO%5MI+Y!G03$ W;G<>E!1#!VEU" _4[3\/
M1W\+ UOW!Z- S+H=E.]R5Q=1&KW*F7$R4V_[,]UWF2?<=_9VT"(E&L^NB\4X
M4524;#W8!X74@C9WD"5RCF&3;J=2@6&Q)5J"<&\?436@JLBS(LW-N % ZPB
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MGC&CY#QZ^BU8=S3+?5(F>K)8Y5M[,6K6-?LEF4<*+<0*D9N"2B/244Q*)2B
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MS%8HS&M6G\B/W=DNF'KQ8'*4=3W;"VR+A6;>TZ1F%",GK-XHZ!#W!5413Z#
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M[8]KTA#5ZR'F5:U;2M0J[E_[PG2R,8RI" !B^>@'+3_-1AU" F?M999.0 ,
M%-GMN8O28HD.40' P[E.0P@(#X" [#H!&6Y3<I<.5<_E_%>,;QBJO6C/;K(]
M)JOH2<U)4%C*7W\D@(@D^A"QI9-W6A6(0CDC5 %#) 8$R?P@ U/\TY4ZW('@
M LJ)SJJ\8K:JLHI_&HJI<XXQSF ?$#B(^.X .^@,ZOA(8AQTIA;F9G-:JQ3C
M*A,J4[&32Y.&Q%9F-HZ5.)8UX",=' 3L6<A,OO6<^GTBN*28'$0(4  ]1\W.
MN0 \9>%%J&&CALS;.-^@F\^+5(9=&$?49&0>1!'VWKA'.'[-)<R._1ZJ8&
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M[#0SCMN>]0^+JO-9-)6B"L#&7)BA[F" JJDXN4$Q5CAN96Z(F,!7JG2 F L
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/V_3;0!H T : - &@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140250380472288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 27,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">enGene Holdings Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001980845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4868 Rue Levy, Suite 220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Saint-Laurent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H4R 2P1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">332-4888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=engn_CommonsharesMember', window );">Commonshares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENGN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember', window );">Warrants, each exercisable for one Common common share, at an exercise price of $11.50 per share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENGNW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=engn_CommonsharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=engn_CommonsharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>a8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:engn="http://engene.com/20231127"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="engn-20231127.xsd" xlink:type="simple"/>
    <context id="c20231127to20231127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
        </entity>
        <period>
            <startDate>2023-11-27</startDate>
            <endDate>2023-11-27</endDate>
        </period>
    </context>
    <context id="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:CommonsharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-27</startDate>
            <endDate>2023-11-27</endDate>
        </period>
    </context>
    <context id="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001980845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">engn:WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-27</startDate>
            <endDate>2023-11-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20231127to20231127"
      id="Fact_19bd0de46b044ca39ca9fe10f63ccb52">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20231127to20231127"
      id="Fact_1a57d70afcb3446c996aa23ebf449804">0001980845</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20231127to20231127"
      id="Fact_c11de306c13a4ad19ac39a5b89a2585b">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityExTransitionPeriod
      contextRef="c20231127to20231127"
      id="Fact_f7354d9afe2c4baaa48fe6e994b351b3">true</dei:EntityExTransitionPeriod>
    <dei:DocumentType
      contextRef="c20231127to20231127"
      id="Fact_3a474c3cd0b14564bc1df8d0899406bb">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20231127to20231127"
      id="Fact_e15f5e7317774f4799b469f72056e9b7">2023-11-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20231127to20231127"
      id="Fact_94ce083d0b124e88855fd6838329e1ae">enGene Holdings Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20231127to20231127"
      id="Fact_db44afcc1ab243bf9f4dd2d2e3958ba6">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20231127to20231127"
      id="Fact_b8c027e36a1944e3bb37c88c468a5351">001-41854</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20231127to20231127"
      id="Fact_03d68e7fef564c30bab6f3c69a3f3cf0">4868 Rue Levy, Suite 220</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20231127to20231127"
      id="Fact_2c71d323120248c19469aecc08c8970b">Saint-Laurent</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20231127to20231127"
      id="Fact_e5023309776344e6abe3bc39072eb58d">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20231127to20231127"
      id="Fact_0a33e3eb295647b8a7e054ebca406b44">H4R 2P1</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20231127to20231127"
      id="Fact_86a3f038e44141dea0045d88c459587b">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20231127to20231127"
      id="Fact_83278cb0fc20428c8db846e1145b0f95">332-4888</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20231127to20231127"
      id="Fact_16a8d6eb3e8d4273b030f8b28f7584d9">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20231127to20231127"
      id="Fact_ec49170c63bd4d78bac6ef8314bb1677">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20231127to20231127"
      id="Fact_d9b7b0596b1943499f163fa58f87b76c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20231127to20231127"
      id="Fact_327111642f23450c8c0b3e8a8e9885ec">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember"
      id="Fact_7d3dbc899a4d4cab87e769e74c0d9db9">Common shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember"
      id="Fact_91b848d0c3ee4d5eb1c9e6d183f87888">ENGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20231127to20231127_StatementClassOfStockAxis_CommonsharesMember"
      id="Fact_c73b4e041cf941eaa9198d40cc41b25b">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember"
      id="Fact_c276d320959b4de1b532dbd9de158016">Warrants, each exercisable for one Common share, at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember"
      id="Fact_fb4a7e565bd14ea8bf43bbe744805ea3">ENGNW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20231127to20231127_StatementClassOfStockAxis_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember"
      id="Fact_946969cf15334e75929a8cf43c102bfa">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20231127to20231127"
      id="Fact_82788dc468f34561b49979e06ee86098">true</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M88Y9K@7&;"3BRD#1.I#< !;'K8K"O%;NDN"0P.L5>+U]\"YP,;6(4#6$%?L
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %F&?5<D'INBK0   /@!   :
M          "  7P2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( %F&?5=ED'F2&0$  ,\#   3              "  6$3  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  *L4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="a8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://engene.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="a8k.htm">a8k.htm</File>
    <File>engn-20231127.xsd</File>
    <File>engn-20231127_def.xml</File>
    <File>engn-20231127_lab.xml</File>
    <File>engn-20231127_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "a8k.htm": {
   "nsprefix": "engn",
   "nsuri": "http://engene.com/20231127",
   "dts": {
    "inline": {
     "local": [
      "a8k.htm"
     ]
    },
    "schema": {
     "local": [
      "engn-20231127.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "engn-20231127_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "engn-20231127_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "engn-20231127_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 36,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://engene.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20231127to20231127",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "a8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231127to20231127",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "a8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "engn_WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20231127",
     "localname": "WarrantsEachExercisableForOneCommonCommonShareAtAnExercisePriceOf1150PerShareMember",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, each exercisable for one Common common share, at an exercise price of $11.50 per share [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "engn_CommonsharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://engene.com/20231127",
     "localname": "CommonsharesMember",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commonshares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://engene.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0000929638-23-003305-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000929638-23-003305-xbrl.zip
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MR:T!>16$"$@Z8\E[,J+)?1"U$# >$CK)XN)1(GKASQ"XEKFYR)"ZELL U4"
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ML))_/LJ2X_*SO,11YBW0JB.I#RS) I>&.;F"1TN85"M@9W4(*XC:=;E[<D:
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MOQ1>T7)K%Y&'[CLCSHRX/%@,5'P%*,AX\NM")#=(N94![MPC:KY/XL=LB%&
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MOK,%Y(9%G#VX4H;!OXL491Y<+*P=YWUA]VIM &HDXM<$K)Z$^S_?GN3X%6L
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M"PH4R':>U,[?%:*IZVX]2#<W!NGD8 'BCA-IK;!1#PU:06RA;R5SZP':A$4
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MNKUL@7'9M++ZPW4OB#-3HY5OL0=U8F!:^1-7R=%*Y;Z(3G(XTK=/<MB%V\4
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M-5+:<(K4G13$1K=C+F-(%R+ 3Y0\\>4%B1\!ME_4E2JU2P&'LKUDZR>XT<6
MPU!Q;G2+YG(MI@W,DM#39UOLD)TRG;!%UGJ\5:EMQM;BIL VM!WS34PA'&+1
MK^(5SFZZF0^ E6JRO!V:]O*LDU1-F XK1;*A/9DIB5" 9'1? !>="9C+5K=
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M9S2\6(%^E__H)CTN?\A_#//^?U!+ P04    " !9AGU75.WZ^YT*  #P;@
M%0   &5N9VXM,C R,S$Q,C=?;&%B+GAM;,V=76_CN!6&[POT/[!N+UI@;,<V
MIML$$RW23+((FDF"B1?;=E ,9)EVA)5%@U(FSK\O*8FV2!Y22D3)NIEX>-[S
M\NLYDLTDRJ>?=YL(_< T"4E\/IB,3@8(QP%9AO'Z?/"<#/TD",/!S]X?__#I
M3\/A+SC&U$_Q$BU>T3\I\9<T7*XQ>OAZOPHCC*:ST>EH,OHX^>D?I?!PR-.C
M,/[]C/^S\!.,6+=Q<K9+PO/!4YINS\;CEY>7T<ML1.AZ/#TYF8S__>7V,7C"
M&W\8QDGJQP$>(*8_2[+&6Q+X:3;F4OIN02-A,!OO^S(J^/^&0C;D3</)=#B;
MC';)<E ,D8=K="+D.TU?S&ER>GHZSJ)[*3,*+=;[:;/50RA?/THB_!6O$/_Z
MZ]<;8_;IF"O&,4YO_06.6)=9>OJZQ>>#)-QL(RS:GBA>P3X1I7L;OCJG?'4F
M?^>K\^>#\[C)\-8<ICE)_<C-.#,_?:Q:-\T'?>=J:6U#OG.YRJS(<0>K7.JF
M^: ?, W)\BI>MC]PM2M7@W],?=H!*GIGS2?0_JB!H4:\Z9:]DOK%NQ3'2[P4
M/7-OR[4SZSJ[V&;.>V\22*X1OXL0JD\G8:Z9X\I/%IDMNQ>N?7_+[*>S,8[2
M1+0,>4LVIZ+A^V7D)\G]ZC$EP>^?R<8/8]%!-K?S@5F0ABF?%R08RS/A3M)<
M*$[(,PVPTI=Y4-^C1?2FY91HR =:Z;Z)V$#X>PD<#W]]'*!P69GD9>V(K% 6
M0=_RV/\^C0_STM?B@LI;Z]- C)6]K)A?H1@'A-UOM^E0FNJ*DHUUSTC=52X6
M+7,_0[H6I015.8V/ #2[JJ1X@^.T/*B+79@HK%7JB@6PZ!I2;G1V"7M5)S;F
M[;D:^CQR9/"K-Y6\<?WE,C"FE*NAPK=I420X&*W)C_$2AWD]L!>',F#_^7Y)
MV(>DBT624C](U<LY%!-7<CGV3KRU$;C V60*X0MKO:R)45HT'OL2#>X#J5@^
MY:)<EG$"#;GM$_>9!,^<^#ES5'" 0L4TY% #W,I&KF@#/$VP:5)/M"#>=%S0
MP/4G]G63,2NK!&5Z9ON0_4;#E+VQOB2;S7,<YD<JZEW=JBFF9= TX ]T= 6B
MS=Q$I#G'*T)(CAV74?NND9J++%,+R@6^%J_V.7XD41B$:1BOO[ W"C3T(P4I
MLT"\)P4$#?#5[5RQ:W0V@6M(\ [M2 2._$[3O$>DSJHJ[RLUK2#5Y-(^I@\4
M\_K ; FR*ST_TJ#WJQ6F"D+5PF*R-F$#?,VVKC"N[,&$<T6BQ^+#H"1 N0)E
MDN,"7F-7R5O67P;>G"/ KW+MO !NDN09T]IE8)3#Q0#(W96$9MY289CZJ5D>
M<+I>)+FNO[5BWGJX8JS;8ZT;+=-0/88>VJ^A"];[DH_@.O+7"JA@K)BN$FM0
M"I*3*^XA4Q/DNM;;-R'>=EQVX5T@%8LG4RG)!() ;G<'$==A$OC1?[!/KUF+
M^BFQ0J4<3V@J!R<5BJ?K0PO8ONK\ LHZ'&7D4<3#*(OWXUS#M(>D]H+#IQU*
M@GKP ?IUS7?^?=1JP@$=R+BD<T9YR;4=SO4.ZI&NYFFLYX+^T0[M)\B[8>EM
MQ)=28.8US^ZHW__8PV?V6=A /*A1:%<T#DB7'%U3#IE7$:[G'.@NL&9!Q*/]
M(!O>-U)SF6&B);E*,^#5/LE7,1OIZU>\#ODW:.+TSM^H6-DDQ31A20.,(4-7
M%%N\31 ;4[P\@@XAQ&/')=BZ8:3> LO\0FJ!K]FI*WHO6?%0/[IA'R9W_\*O
M(+X&C<2OIFD,L.+HEF#8W(XPE",8+F(H"R(6[0/%IGTC-9<9XEB1RR"#7EV1
M?!U&^.YYL]#.\DQAB=]RN#&Z!S.WU&J^=F 5N6"5-Z.\O0^4 AM#JA<38O.@
ME+%4';HB<N[O;I:L),)5\5U)"YX56HE5H[8QN 9GMQ3;.[$C;<L5?#,-DD4]
MHKUJG\D;MP.J T.:7!16[ZXJY"8."-T2F@T@^U&[2_+,[B&OEV0)OY6NE2%5
M2T5&XYJQ^KNMG#I=V>NGVD%4D:3\D/^P)"(4%7K$$_I04/6 (._:,:BXK,ER
MB=7HIZM"N]I@N@[C]2^4O*1/EV2S]6/XS;Y5*1660=FXH$!?MX5DZ\)>0.9,
M43A"@7()*C1]J!7[WI(W;0)4&V"27!,6W\YJ83=GG[63D%=E?FX$%X)1)E<!
M(&M> IJI8_Y-_A7PPVE[\G?H$"\.)GN!O7DG2?U5!X'7,A3:#8Y=H7ZQ7#+6
MDN++;1CC"<BZ12?!#NH:TPZXNL7=W(&==U.> +X(?! O$)>@^[@7;XQL>TK>
ML/P0]T"*#+[1\WCD3VN2/ZU)_K05\J=MDS]])_G3&N3/7T@_R9_6)7_Z=O*G
M5>1/CTW^K";YLYKDSUHA?]8V^;-WDC^K0S[;L)Y>]6=UV9^]G?U9%?NSH[!_
MR5[>TSEY47__O4(%<5]6N:+^X-D*\YI]+>*5+(UW'N<'0%S1(]*!780XAY?<
M0ODA 61<]>N8\.PTZ9X^4/(CC#7@ZD@AUC6I*^ 5XU:HA_NHA3Z4JO&_/P$5
MLAX5@6F/H4JP[(6E')0LL"9 YZXO_?D)J_6Z+TO B[Z0.+OBYX;M7.XE[WK7
M^E**?J'/@SW"6]TQ\ *OK[#MZEY\%P.\M)>=.L;W@22I'_TWW!J_ 6830B@K
M0E= 2[:M8 WU4 MN/5%#/)<@ING-][&L^PH!;]P!"_92#@@_X-K!,TYX_Q3[
M /10J)B@'&KR@).2D;/GF^B>QL>;J%(O>ZO-FWI )[@!Q+YP,H%EU?[!)EIF
M^Y3Q)W=&#T\DAG],S!0N)J.'&Q"GFKFBSN!K(@^4>UDKRII[\8,SQHTAU8LI
MDZ@J!8VP0U>W_MLPX8\$2.;^(H+O^:!"NMDKBL9W><G/[>T=LK;?U_4,<4,7
M$?0MBQWY,5"VS2*U5A>Z=4MB^9X-^'0-+3_DNTGQ1OV=M0H5"&])Y0S@O6<[
M$*OV]4"6LW28>1QE@EX1K>\B2#6XY#:R]PDPW8I?!\_TP<$S90.83!=S/FP%
M,E.XF*(>;O(T'\7,V;-\8%_CDWP@N9>]Y,^,G$S_NO@;$J(C/\O'M#ND>D5E
M2%7E_BD^H$/[6-Z1.?7Y\_$?7S<+$@$/8; HBJF!B@9\ GZN$#5;FR@U97AW
M!!41E(=Z\*@&VUZ16HLKTPJ(!;!&G_:9E3I6^ %CQ:246 -")2=7;$*F)BIU
MK2?#>%P.X5T@%8LGLR?)!'5 ;G>W[JM=\,0V P._DFN3*+=P6>+@-EXV='TK
M![RK;N=:BB<B2(1Z\"NYU@TC]188OK.7U>K=77=Z![TX7L<9H)/)]*<,4M[R
MG3_-B<3)D\^0^8*!LRBS0)Q] H)W\FD8$9_SI"F?%=X0G]84KQQ W_+0T1_^
M;-PK4F]UE>-23<S1M/NX0_,WG_)?1$^N_.#I:H=I$";\<.&:T/L8Y_WG_S[R
M45RD%W&AP@\T#/#]:C+Y>/* :18&V6ZQAV(A6^FA276U,"!WY=GBX(SUW5J?
MGG#^@##S1OA@CE:$(GZFG3NC(/^25=,'Y*?(CX4<HRWOAG^T_<MD,OIX@K:L
M"C-E3RXZ;181Z8A:^;+70F_[ZV9[,RG^?E")A5OVBO_5N:(IS/]*F_=_4$L#
M!!0    ( %F&?5=_\Q9.-P<  "=0   5    96YG;BTR,#(S,3$R-U]P<F4N
M>&ULU5Q=<^(V%'WO3/\#I<_@&+H?9#:[0[/)#M-L8 *=;?NR(VP!FK4E1C()
M^?>5C$2P+,OF*RN_D,0Z'-US[[$L;FP^?%K'4>,14H8(OFKZ[8MF ^* A C/
MKYHKU@(L0*CYZ>.OOWSXK=7Z C&D((%A8_K<^),2$%(4SF%C]#"<H0@V.MUV
MK^VWW_COWN\,MUKB[1'"/R[%RQ0PV.#38G:Y9NBJN4B2Y:7G/3T]M9^Z;4+G
M7N?BPO?^^7HW#A8P!BV$60)P )L-CK]DZ<$[$H DC7GG[>LIC11!U]O.58@0
M?[44K"4.M?Q.J^NWURQLRA#%<(5)%'R=PTM-?J_7\]+1+903(0OU5C;/7J.Q
MR1\E$7R LX;X^??#H/#=/4\@/ R3.S"%$9\R?7ORO(1738;B9035L06%,S-/
M1.F61F2G)[+COQ79^?V%V3LFO+DPTX0D(#I-G"E?/M;<-,<'?7^JU-I"OC]E
MEOE)#E\ARSO3'!_T"%)$PAL<GC]P?:I3!3]. 'T%J^0G.U[ ^:/>(U2(Y_SJ
MTPY(O"'^3()5#''2Q[QH"4J>!WA&:)Q>%<ICYFR8Q]3I^G[G71J1G6\WPB6%
MC /3D3M^(#,97"<0AS!4TXE8#].0SJCFC$B0F282US]"\X5@?)JT"@P&[3EY
M]$*(/"%4_)(J3M7R/[Y?$W[A[T]90D&0**9(5.2J:1SC$0HQVIAW]D WN;E#
M+.';$C8!TY=JRG M"!FT$7%LZ#/ IJG=^4YI#L!R$S^,$J:.O B1![[S4S2!
MHNC7$6!L.!LG)/C17R.F22K%26$6W,^0MQO%9Q(#A'5G%0*4O0R  Y3DSW!Q
MA)L^C@EF"\!/XJ\PGD*:<WX18&O_/" ;W^X"T:?96 $-%!__-;,ZY+> $N$M
M^5PX:04+%&T7EADEL36;I(*6W4@O&WFR1D(:)A)"0TBOFA?B\P+GF$%*Y6)N
M49-*B797_%,4]!N@%."$W8!@<;.&-$!,G-RWA XQW,2^>1T+!7V^UDH4'%$4
MP.',]]]<\*MG.FQTQ!EGD&4XRPR.>O+\V:QBZK-$(<\*_T1GQ2N6K/QB0RJL
MW-G$%W*FBXJ!Z\2+RBNFS[;](-4OY=G\&4A%YBQD/V-5/FHKQW?/<,#5Z'N?
M$I1Q2[>#.K\,M7&?<$8M=M.0##@[Y(A;\]DE5A$VDVZYA%&S'#7P9I]'&XJ(
M;R,PUZIJ'),9T<9<KJM-1N7":B0GONJ=\W3=]G@^\S6TX+PU8K036,.X7/$J
MLO8^I34RZ8!.#1QPBU@ HG\AH+?\B'[=*4%I+LBAZN #N[2]G9"CDU[HUL8+
M&R^7N\& ,_HA@ZN/(XKE'>B)#*%TQ1\.NV(C[!9%\'YE: (4#6?VHKO#+I>^
M1$SEBN=Y9*'?.%_H!SA'HH.-DWL0F]O)9DBFX#K$_:);1>U9>)U+%O^M\\6_
MYB(IB 8XA.N_X+.Q^@683/ES&/?K;Y>UIP%R9-(![YQWP  'A"X)396F+95K
MLN)BGJ]):%X-*KTCXXZ2=[COE7TD[^F<$FKIH_?.^V@"UH.0ZT8SM+DAR;)Y
M*,%FO%.(==\UU63NZ9="4NF4GO-.Z8<AE\SD#R'1-[K$@LLXQ(ASWQWE\O9T
MAI%0]:1<;C<6A=^I:(M.15MTZFD+7=[1MNB\V,+E7F51^-V*MNA6M$6WGK;0
MY1UMB^Z++5QN8&;"O^:_#NF$/.DWUY2@3);81=7&$(72#K/#+ITR@\L=S$SP
MZ>YY2$>4/*+-7?*%CBB FFR1@];&&W:1AQDDQZE<XGY'4UE\\_'*NEYD(<;%
M0D%JXP:SJ .7"<6EJN]^FU-&/B(L =%_:%G8WK !34[0@+7Q@TW@8:[0&)4W
M7.Z"BNM=GT)@<(-I2*8G.^1RQ2TB*M<XRZ&JZG)G4SP3%XT6!)O_@U4T+!.3
M'W:YPB5B*E<YSZ,J[7+O<0R#%>62_,YT(@1KE2X:ELG)#[M<Z1(QE2N=YU&5
M=KEW.*% /(L[?HZG)-+*;!R3:='&7"ZP34;EZFHDZHXDE_M_]R03M.&F0PM"
MYL>(<+G8Y9(JE]Q(I0KO<H=/K40WZV !\!P:;D"P0;15/ MQN?851.V]FF>Y
M5/7=;^3=Q)#.N:HOE#PEBVL2+P$V?SBW(C.?S J0+ENBNL0]/YL54"J#N-_<
MNUGSU0TS)/1N;J4SNZ,0EK6& 58#7Y2)V]<4!C[E")<;>=_X2I? ](&T%9;_
M_]9O5K5B9+H*,"X;H8JLRBXH(%,6<+F;-R81"I"0]!4DW+I _S!0#%#[!0/
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M]'^/3[Y@ O\8NKZ<7\KNE74!$WJ6'#Y>X?H__/SZ?3(YC:U^ ;3T7W_Y_N
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MN@LNQAT$_?6%/NPQ*)*.7KIC8R%F\V^MM(EF.;$)TN7;XT%5"114B$;0NAT
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MM-GAM/TIHRA2C<;'25:0HA:Q-1$9/'<D:#>-#X!P[^@=5UWI"BV*E&AV-9
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M=0Y5VWE42UG2;X3YTD\R;$[@*!=L<R3K&P#?8PV5O*ACC9#_*.LFND$TE]5
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MOBWSEU=?D^D[OU.6/AT]HZ_A\8?XK<+_ 5!+ 0(4 Q0    ( %F&?5=2BR'
MBQP  &V=   '              "  0    !A.&LN:'1M4$L! A0#%     @
M689]5Z+,I;[H P  $A(  !$              ( !L!P  &5N9VXM,C R,S$Q
M,C<N>'-D4$L! A0#%     @ 689]5\1X^$<M!P  8T<  !4
M ( !QR   &5N9VXM,C R,S$Q,C=?9&5F+GAM;%!+ 0(4 Q0    ( %F&?5=4
M[?K[G0H  /!N   5              "  2<H  !E;F=N+3(P,C,Q,3(W7VQA
M8BYX;6Q02P$"% ,4    " !9AGU7?_,63C<'   G4   %0
M@ 'W,@  96YG;BTR,#(S,3$R-U]P<F4N>&UL4$L! A0#%     @ 689]5T^:
M.D:I$P  '7T   \              ( !83H  &5X:&EB:70Q,"TQ+FAT;5!+
M 0(4 Q0    ( %F&?5<-(&LT*3\  #4H 0 /              "  3=.  !E
M>&AI8FET,3 M,BYH=&U02P$"% ,4    " !9AGU7;T8)17<.  !>*   #P
M            @ &-C0  97AH:6)I=#DY+3$N:'1M4$L%!@     (  @ ] $
' #&<      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
